PUBLICATIONS of FCAM2

PUBLICATIONS

白澤グループ

<原 著>

2018年

1. Naemura M, Kuroki M, Tsunoda T, Arikawa N, Sawata Y, Shirasawa S, Kotake Y: The Long Noncoding RNA OIP5-AS1 Is Involved in the Regulation of Cell Proliferation. Anticancer Res, 38(1):77-81, 2018

2. Okamoto H, Matsukawa T, Doi S, Tsunoda T, Sawata Y, Naemura M, Ohnuki K, Shirasawa S, Kotake Y: A novel resveratrol derivative selectively inhibits the proliferation of colorectal cancer cells with KRAS mutation. Mol Cell Biochem, in press

2017年

1. 1. Kalimutho M, Bain AL, Mukherjee B, Nag P, Nanayakkara DM, Harten SK, Harris JL, Subramanian GN, Sinha D, Shirasawa S, Srihari S, Burma S, Khanna KK: Enhanced dependency of KRAS mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae. Mol Oncol, 11(5):470-490, 2017

2. Tajiri H, Uruno T, Shirai T, Takaya D, Matsunaga S, Setoyama D, Watanabe M, Kukimoto-Niino M, Oisaki K, Ushijima M, Sanematsu F, Honma T, Terada T, Oki E, Shirasawa S, Maehara Y, Kang D, Côté JF, Yokoyama S, Kanai M, Fukui Y: Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1. Cell Rep, 19(5):969-980, 2017

3. Gong J, Chen Y, Yang L, Pillai R, Shirasawa S, Fakih M: MEK162 Enhances Antitumor Activity of 5-Fluorouracil and Trifluridine in KRAS-mutated Human Colorectal Cancer Cell Lines. Anticancer Res, 37(6):2831-2838, 2017

4. Radhakrishnan H, Ilm K, Walther W, Shirasawa S, Sasazuki T, Daniel PT, Gillissen B, Stein U: MACC1 regulates Fas mediated apoptosis through STAT1/3 - Mcl-1 signaling in solid cancers. Cancer Lett, 403:231-245, 2017

5. Nishi K, Luo H, Ishikura S, Doi K, Iwaihara Y, Wills L, Baillie GS, Sakata T, Shirasawa S, Tsunoda T: Apremilast Induces Apoptosis of Human Colorectal Cancer Cells with Mutant KRAS. Anticancer Res, 37(7):3833-3839, 2017

6. Nishi K, Luo H, Nakabayashi K, Doi K, Ishikura S, Iwaihara Y, Yoshida Y, Tanisawa K, Arai T, Mori S, Sawabe M, Muramatsu M, Tanaka M, Sakata T, Shirasawa S, Tsunoda T: An Alpha-kinase 2 Gene Variant Disrupts Filamentous Actin Localization in the Surface Cells of Colorectal Cancer Spheroids. Anticancer Res, 37(7): 3855-3862, 2017

7. Yoo BH, Khan IA, Koomson A, Gowda P, Sasazuki T, Shirasawa S, Gujar S, Rosen K: Oncogenic RAS-induced downregulation of ATG12 is required for survival of malignant intestinal epithelial cells. Autophagy, 1-18, 2017

8. Nishi K, Iwaihara Y, Tsunoda T, Doi K, Sakata T, Shirasawa S, Ishikura S: ROS-induced cleavage of NHLRC2 by caspase-8 leads to apoptotic cell death in the HCT116 human colon cancer cell line. Cell Death Dis, 8(12):3218, 2017

9. Gondo K, Ike A, Ogawa M, Shirai K, Sugihara M, Nishikawa H, Iwata A, Kawamura A, Mori K, Zhang B, Miura S.I, Yasunaga S, Saku K: Is a bare-metal stent still useful for improving the outcome of percutaneous coronary intervention? From the FU-Registry. J Cardiol, 69, 652-659, 2017

10. Yotsumoto F, Fukagawa S, Miyata K, Nam S.O, Miyahara D, Odawara T, Manabe S, Ishikawa T, Yasunaga S, Miyamoto S: HB-EGF is a promising therapeutic target for lung cancer with secondary mutation of EGFRT790M. Anticanceer Res, 37(7), 3825-3831, 2017

11. Miyata K, Yotsumoto F, Fukagawa S, Kiyoshima C, Nam S.O, Urushiyama D, Ito T, Katsuda T, Kurakazu M, Araki R, Sanui A, Miyahara D, Murata M, Shirota K, Yagi H, Takono T, Yasunaga S. & Miyamoto S.: Serum heparin-binding epidermal growth factor-like growth factor (HB-EGF) as a biomarker for primary ovarian cancer. Anticanceer Res, 37(7), 3655-3660, 2017

12. Fukagawa S, Yotsumoto F, Odawara T, Manabe S, Ishikawa T,Miyata K, Yasunaga S, Miyamoto S.: Antitumor effect of intravenous administration of BK-UM, a novel inhibitor of HB-EGF, in ovarian cancer therapy. Anticanceer Res, 37(7), 3891-3896, 2017

13. Shiiba M, Zhang B, Miura S.I, Ike A, Nose D, Kuwano T, Imaizumi S, Sugihara M, Iwata A, Nishikawa H, Kawamura A, Shirai K, Yasunaga S, Saku K.: Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry. J Cardiol, 69, 652-659, 2017

14. Urushihara D, Suda W, Ohnishi E, Araki R, Kiyoshima C, Kurakazu M, Sanui A, Yotsumoto F, Murata M, Nabeshima K, Yasunaga S, Miyamoto S & Hata K: Microbiome profile of the amniotic fluid as a predictive biomarker of perinatal outcome. Sci Rep, 7(1), 12171, 2017

15. Matsuoka Y, Ike-A, Ogawa M, Gondo K, Sugihara M, Nose D, Nishikawa H, Iwata A, Kawamura A, Mori K, Zhang B, Yasunaga, S, Miura S.I. & Saku K: Sex difference between target levels of cholesterol-related parameters and post-PCI long-term clinical outcomes: from the FU-Registry. J Cardiol, in press.

2016年

1. Dunne PD, Dasgupta S, Blayney J, McArt DG, Redmond KL, Weir JA, Bradley CA, Sasazuki T, Shirasawa S, Wang T, Srivastava S, Ong CW, Arthur K, Salto-Tellez M, Wilson RH, Johnston PG, Van Schaeybroeck S : EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. Clin Cancer Res, 22(1):230-242, 2016

2. Naemura M, Tsunoda T, Inoue Y, Okamoto H, Shirasawa S, Kotake Y : ANRIL regulates the proliferation of human colorectal cancer cells in both two- and three-dimensional culture. Mol Cell Biochem, 412(1-2):141-146, 2016

3. Goulielmaki M, Koustas E, Moysidou E, Vlassi M, Sasazuki T, Shirasawa S, Zografos G, Oikonomou E, Pintzas A : BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells. Oncotarget, 7(8):9188-9221, 2016

4. Lapa GB, Tsunoda T, Shirasawa S, Baryshnikova MA, Evseev GG, Afanasyeva DA, Chigorina EA : Synthesis of new congeners of 1-methyl-3-aminoisoquinolines, evaluation of their cytotoxic activity, in silico and in vitro study of their molecular targets as PDE4B. Chem Biol Drug Des, 87(4):575-582, 2016

5. Toda K, Kawada K, Iwamoto M, Inamoto S, Sasazuki T, Shirasawa S, Hasegawa S, Sakai Y : Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase. Neoplasia, 18(11):654-665, 2016

6. Ishikura S, Tsunoda T, Nakabayashi K, Doi K, Koyanagi M, Hayashi K, Kawai T, Tanaka Y, Iwaihara Y, Luo H, Nishi K, Okamura T, Shirasawa S : Molecular mechanisms of transcriptional regulation by the nuclear zinc-finger protein Zfat in T cells. Biochim Biophys Acta, 1859(11):1398-1410, 2016

7. Kotake Y, Naemura M, Kitagawa K, Niida H, Tsunoda T, Shirasawa S, Kitagawa M : Oncogenic Ras influences the expression of multiple lncRNAs. Cytotechnology, 68(4):1591-1596, 2016

8. Swain A, Kulkeaw K, Tanaka Y, Nakanishi Y, Shirasawa S, Sugiyama D : DBA lectin binds to highly proliferative mouse erythroleukemia cells. Anticancer Res, 36(7): 3625-3633, 2016

9. Luo H, Umebayashi M, Doi K, Morisaki T, Shirasawa S, Tsunoda T : Resveratrol overcomes cellular resistance to vemurafenib through dephosphorylation of AKT in BRAF-mutated melanoma cells. Anticancer Res, 36(7):3585-3589, 2016

10. Ishikura S, Iwaihara Y, Tanaka Y, Luo H, Nishi K, Doi K, Koyanagi M, Okamura T, Tsunoda T, Shirasawa S : The nuclear zinc finger protein Zfat maintains FoxO1 protein levels in peripheral T cells by regulating activities of autophagy and Akt signaling pathway. J Biol Chem, 291(29):15282-15291, 2016

11. Bordonaro M, Shirasawa S, Lazarova DL : In hyperthermia increased ERK and WNT signaling suppress colorectal cancer cell growth. Cancers (Basel), 8(5) pii:E49, 2016

12. Hara K, Tajima G., Okada S, Tsumura M, Kagawa R, Shirao K, Ohno Y, Yasunaga S, Ohtsubo M, Hata I, Sakura N, Shigematsu Y, Takihara Y. & Kobayashi M : Significance of ACADM mutations identified through newborn screening of MCAD deficiency in Japan. J Mol Genet Metabol, 118(1), 9-14, 2016

13. Ohno Y, Suzuki-Takedachi K, Yasunaga S, Kurogi T, Santo M, Masuhiro Y, Hanazawa S, Ohtsubo M, Naka K. & Takihara Y : Manipulation of cell cycle and chromatin configuration by means of cell-penetrating Geminin. PLoS ONE, 11(5), e0155558, 2016

14. Nam S.O, Yotsumoto F, Miyata K, Fukagawa S, Odawara T, Manabe S, Ishikawa T, Kuroki M, Yasunaga S. & Miyamoto S : Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy. Anticanceer Res, 36(7), 3651-3657, 2016

15. Shirasu N. & Yasunaga S : Duplex PCR-RFLP for the simultaneous genotypeing of single nucleotide polymerisms in ADH1B abd ALDH2 genes. Anal Sci, 32(12), 1363-1366, 2016


2015年

1. Ishikura S, Ogawa M, Doi K, Matsuzaki H, Iwaihara Y, Tanaka Y, Tsunoda T, Hideshima H, Okamura T, Shirasawa S : Zfat-deficient CD4+ CD8+ double-positive thymocytes are susceptible to apoptosis with deregulated activation of p38 and JNK. J Cell Biochem, 116(1):149-157, 2015

2. Tanaka Y, Inoue-Yokoo T, Kulkeaw K, Yanagi-Mizuochi C, Shirasawa S, Nakanishi Y, Sugiyama D. : Embryonic hematopoietic progenitor cells reside in muscle before bone marrow hematopoiesis. PLoS One, 10(9):e0138621, 2015

3. Kojima N, Tanaka Y, Kulkeaw K, Nakanishi Y, Shirasawa S, Sugiyama D. : Apoptosis-inducing Factor, Mitochondrion-associated 2, Regulates Klf1 in a Mouse Erythroleukemia Cell Line. Anticancer Res, 35(8):4493-4499, 2015

4. Tsunoda T, Ishikura S, Doi K, Iwaihara Y, Hidesima H, Luo H, Hirose Y, Shirasawa S. : Establishment of a Three-dimensional Floating Cell Culture System for Screening Drugs Targeting KRAS-mediated Signaling Molecules. Anticancer Res, 35(8):4453-4459, 2015

5. Iwaihara Y, Ishikura S, Doi K, Tsunoda T, Fujimoto T, Okamura T, Shirasawa S. : Marked Reduction in FoxO1 Protein by its Enhanced Proteasomal Degradation in Zfat-deficient Peripheral T-Cells. Anticancer Res, 35(8):4419-4423, 2015

6. Yoo BH, Zagryazhskaya A, Li Y, Koomson A, Khan IA, Sasazuki T, Shirasawa S, Rosen K. : Upregulation of ATG3 contributes to autophagy induced by the detachment of intestinal epithelial cells from the extracellular matrix, but promotes autophagy-independent apoptosis of the attached cells. Autophagy, 11(8):1230-1246, 2015

7. Tochio N, Umehara T, Nakabayashi K, Yoneyama M, Tsuda K, Shirouzu M, Koshiba S, Watanabe S, Kigawa T, Sasazuki T, Shirasawa S, Yokoyama S. : Solution structures of the DNA-binding domains of immune-related zinc-finger protein ZFAT. J Struct Funct Genomics, 16(2):55-65, 2015

2014年

1. Wang L, Gala M, Yamamoto M, Pino MS, Kikuchi H, Shue DS, Shirasawa S, Austin TR, Lynch MP, Rueda BR, Zukerberg LR, Chung DC : Adrenomedullin is a therapeutic target in colorectal cancer. Int J Cancer, 134(9):2041-2050, 2014

2. Organ SL, Hai J, Radulovich N, Marshall CB, Leung L, Sasazuki T, Shirasawa S, Zhu CQ, Navab R, Ikura M, Tsao MS : p120RasGAP Is a Mediator of Rho Pathway Activation and Tumorigenicity in the DLD1 Colorectal Cancer Cell Line. PLoS ONE, 9(1):e86103, 2014

3. Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F : KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer, 134(9):2146-2155, 2014

4. Van Schaeybroeck S, Kalimutho M, Dunne PD, Carson R, Allen W, Jithesh PV, Redmond KL, Sasazuki T, Shirasawa S, Blayney J, Michieli P, Fenning C, Lenz HJ, Lawler M, Longley DB, Johnston PG : ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. Cell Rep, 7(6):1940-1955, 2014

5. Doi K, Ishikura S, Shirasawa S : The roles of ZFAT in thymocyte differentiation and homeostasis of peripheral naive T-cells. Anticancer Res, 34(8):4489-4495, 2014

6. Tsunoda T, Ishikura S, Doi K, Matsuzaki H, Iwaihara Y, Shirasawa S : Resveratrol induces luminal apoptosis of human colorectal cancer HCT116 cells in three-dimensional culture. Anticancer Res, 34(8): 4551-4555, 2014

7. Tanaka Y, Kulkeaw K, Inoue T, Tan KS, Nakanishi Y, Shirasawa S, Sugiyama D : Dok2 likely down-regulates Klf1 in mouse erythroleukemia cells. Anticancer Res, 34(8): 4561-4567, 2014

8. Sun Q, Luo T, Ren Y, Florey O, Shirasawa S, Sasazuki T, Robinson DN, Overholtzer M : Competition between human cells by entosis. Cell Res, 24(11):1299-1310, 2014

9. Iwamoto M, Kawada K, Nakamoto Y, Itatani Y, Inamoto S, Toda K, Kimura H, Sasazuki T, Shirasawa S, Okuyama H, Inoue M, Hasegawa S, Togashi K, Sakai Y : Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS. J Nucl Med, 55(12):2038-2044, 2014

2013年

1. Vartanian S, Bentley C, Brauer MJ, Li L, Shirasawa S, Sasazuki T, Kim JS, Haverty P, Stawiski E, Modrusan Z, Waldman T, Stokoe D : Identification of mutant KRas-dependent phenotypes using a panel of isogenic cell lines. J Biol Chem, 288(4):2403-2413, 2013

2. Yotsumoto F, Tokunaga E, Oki E, Maehara Y, Yamada H, Nakajima K, Nam SO, Miyata K, Koyanagi M, Doi K, Shirasawa S, Kuroki M, Miyamoto S : Molecular hierarchy of heparin-binding epidermal growth factor-like growth factor-regulated angiogenesis in triple negative breast cancer. Mol Cancer Res, 11(5):506-517, 2013

3. Kiyohara C, Miyake Y, Koyanagi M, Fujimoto T, Shirasawa S, Tanaka K, Fukushima W, Sasaki S, Tsuboi Y, Yamada T, Oeda T, Shimada H, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M; Fukuoka Kinki Parkinson's Disease Study Group : MDR1 C3435T polymorphism and interaction with environmental factors in risk of Parkinson's disease: a case-control study in Japan. Drug Metab Pharmacokinet, 28(2):138-143, 2013

4. Matsuzaki H, Fujimoto T, Tanaka M, Shirasawa S : Tespa1 is a novel component of mitochondria-associated endoplasmic reticulum membranes and affects mitochondrial calcium flux. Biochem Biophys Res Commun, 433(3):322-326, 2013

5. Fujimoto T, Matsuzaki H, Tanaka M, Shirasawa S : Tespa1 protein is phosphorylated in response to store-operated calcium entry. Biochem Biophys Res Commun, 434(1):162-165, 2013

6. Ogawa M, Okamura T, Ishikura S, Doi K, Matsuzaki H, Tanaka Y, Ota T, Hayakawa K, Suzuki H, Tsunoda T, Sasazuki T, Shirasawa S : Zfat-deficiency results in a loss of CD3ζ phosphorylation with dysregulation of ERK and Egr activities leading to impaired positive selection. PLoS ONE, 8(10):e76254, 2013

2012年

1. Zhang Y, Kobayashi T, Hayashi Y, Yoshioka R, Shiraishi A, Shirasawa S, Higashiyama S, Ohashi Y : Important Role of Epiregulin in Inflammatory Responses During Corneal Epithelial Wound Healing. Invest Ophthalmol Vis Sci, 53(4):2414-2423, 2012

2. Liu N, Matsumoto M, Kitagawa K, Kotake Y, Suzuki S, Shirasawa S, Nakayama KI, Nakanishi M, Niida H, Kitagawa M : Chk1 phosphorylates the tumour suppressor Mig-6, regulating the activation of EGF signalling. EMBO J, 31(10):2365-2377, 2012

3. Ota T, Doi K, Fujimoto T, Tanaka Y, Ogawa M, Matsuzaki H, Kuroki M, Miyamoto S, Shirasawa S, Tsunoda T : KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res, 32(6):2271-2276, 2012

4. Yoshida Y, Tsunoda T, Doi K, Fujimoto T, Tanaka Y, Ota T, Ogawa M, Matsuzaki H, Kuroki M, Iwasaki A, Shirasawa S : ALPK2 is crucial for luminal apoptosis and DNA repair-related gene expression in a three-dimensional colonic-crypt model. Anticancer Res, 32(6):2301-2308, 2012

5. Yuen HF, Abramczyk O, Montgomery G, Chan KK, Huang YH, Sasazuki T, Shirasawa S, Srivastava G, Chan KW, Fennell D, Janne P, El-Tanani M, Murray JT : Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells. Biosci Rep, 32(4):413-422, 2012

6. Tsunoda T, Ota T, Fujimoto T, Doi K, Tanaka Y, Yoshida Y, Ogawa M, Matsuzaki H, Hamabashiri M, Tyson DR, Kuroki M, Miyamoto S, Shirasawa S : Inhibition of Phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model. Mol Cancer, 11(1):46, 2012

7. Kozako T, Aikawa A, Shoji T, Fujimoto T, Yoshimitsu M, Shirasawa S, Tanaka H, Honda SI, Shimeno H, Arima N, Soeda S : High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T-cell leukemia cells. Int J Cancer, 131(9):2044-2055, 2012

8. Gulhati P, Zaytseva YY, Valentino JD, Stevens PD, Kim JT, Sasazuki T, Shirasawa S, Lee EY, Weiss HL, Dong J, Gao T, Evers BM : Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. Carcinogenesis, 33(9):1782-1790, 2012

10. Ikonomou G, Kostourou V, Shirasawa S, Sasazuki T, Samiotaki M, Panayotou G : Interplay between oncogenic K-Ras and wild-type H-Ras in Caco2 cell transformation. J Proteomics, 75(17):5356-5369, 2012

11. Doi K, Fujimoto T, Okamura T, Ogawa M, Tanaka Y, Mototani Y, Goto M, Ota T, Matsuzaki H, Kuroki M, Tsunoda T, Sasazuki T, Shirasawa S : ZFAT plays critical roles in peripheral T cell homeostasis and its T cell receptor-mediated response. Biochem Biophys Res Commun, 425(1):107-112, 2012

12. Fujimoto T, Shirasawa S : Identification of KRAP-expressing cells and the functional relevance of KRAP to the subcellular localization of IP3R in the stomach and the kidney. Int J Mol Med, 30(6):1287-1293, 2012

13. Matsuzaki H, Fujimoto T, Ota T, Ogawa M, Tsunoda T, Doi K, Hamabashiri M, Tanaka M, Shirasawa S : Tespa1 is a novel IP3R-binding protein in T- and B-lymphocytes. FEBS Open Bio, 2:255-259, 2012

2011年

1. Miyasaka K, Fujimoto T, Kawanami T, Takiguchi S, Jimi A, Funakoshi A, Shirasawa S : Pancreatic hypertrophy in Ki-ras-induced actin-interacting protein gene knockout mice. Pancreas, 40(1):79-83, 2011

2. Doi K, Fujimoto T, Koyanagi M, Tsunoda T, Tanaka Y, Yoshida Y, Takashima Y, Kuroki M, Sasazuki T, Shirasawa S : ZFAT is a critical molecule for cell survival in mouse embryonic fibroblasts. Cell Mol Biol Lett, 16(1):89-100, 2011

3. Van Schaeybroeck S, Kyula JN, Fenton A, Fenning CS, Sasazuki T, Shirasawa S, Longley DB, Johnston PG : Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17. Cancer Res, 71(3):1071-1080, 2011

4. Sasawatari S, Okamura T, Kasumi E, Tanaka-Furuyama K, Yanobu-Takanashi R, Shirasawa S, Kato N, Toyama-Sorimachi N : The solute carrier family15A4 regulates TLR9 and NOD1 functions in the innate immune system and promotes colitis in mice. Gastroenterology, 140(5):1513-1525, 2011

5. Fujimoto T, Machida T, Tanaka Y, Tsunoda T, Doi K, Ota T, Okamura T, Kuroki M, Shirasawa S : KRAS-induced actin-interacting protein is required for the proper localization of inositol 1,4,5-trisphosphate receptor in the epithelial cells. Biochem Biophys Res Commun, 407(2):438-443, 2011

6. Fujimoto T, Machida T, Tsunoda T, Doi K, Ota T, Kuroki M, Shirasawa S : KRAS-induced actin-interacting protein regulates inositol 1,4,5-trisphosphate-receptor-mediated calcium release. Biochem Biophys Res Commun, 408(2):214-217, 2011

7. Fujimoto T, Machida T, Tsunoda T, Doi K, Ota T, Kuroki M, Shirasawa S : Determination of the critical region of KRAS-induced actin-interacting protein for the interaction with inositol 1,4,5-trisphosphate receptor. Biochem Biophys Res Commun, 408(2): 282-286, 2011

8. Kiyohara C, Miyake Y, Koyanagi M, Fujimoto T, Shirasawa S, Tanaka K, Fukushima W, Sasaki S, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M : APOE and CYP2E1 polymorphisms, alcohol consumption, and Parkinson's disease in a Japanese population. J Neural Transm, 118:1335-1344, 2011

9. Kiyohara C, Miyake Y, Koyanagi M, Fujimoto T, Shirasawa S, Tanaka K, Fukushima W, Sasaki S, Tsuboi Y, Yamada T, Oeda T, Shimada H, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M, Study Group FK : Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population. BMC Neurol, 11(1):89, 2011

10. Fujimoto T, Shirasawa S : KRAS-induced actin-interacting protein: A potent target for obesity, diabetes and cancer. Anticancer Res, 31(7):2413-2417, 2011

11. Tsunoda T, Takashima Y, Yoshida Y, Doi K, Tanaka K, Fujimoto T, Machida T, Ota T, Koyanagi M, Kuroki M, Sasazuki T, Shirasawa S : Oncogenic KRAS regulates miR-200c and miR-221/222 in a 3D-specific Manner in colorectal cancer cells. Anticancer Res, 31(7):2453-2459, 2011

12. Yoshida Y, Tsunoda T, Doi K, Tanaka K, Fujimoto T, Machida T, Ota T, Koyanagi M, Takashima Y, Sasazuki T, Kuroki M, Iwasaki A, Shirasawa S : KRAS-mediated up-regulation of RPM2 expression is essential for the proliferation of colorectal cancer cell lines. Anticancer Res, 31(7):2535-2539, 2011

13. Makrodouli E, Oikonomou E, Koc M, Andera L, Sasazuki T, Shirasawa S, Pintzas A : BRAF and RAS oncogenes regulate Rho GTPase pathways to mediate migration and invasion properties in human colon cancer cells: a comparative study. Mol Cancer, 10:118, 2011

14. Yoo BH, Wang Y, Erdogan M, Sasazuki T, Shirasawa S, Corcos L, Sabapathy K, Rosen KV : Oncogenic ras-induced down-regulation of pro-apoptotic protease caspase-2 is required for malignant transformation of intestinal epithelial cells. J Biol Chem, 286(45):38894-38903, 2011

15. Nakabayashi K, Tajima A, Yamamoto K, Takahashi A, Hata K, Takashima Y, Koyanagi M, Nakaoka H, Akamizu T, Ishikawa N, Kubota S, Maeda S, Tsunoda T, Kubo M, Kamatani N, Nakamura Y, Sasazuki T, Shirasawa S : Identification of independent risk loci for Graves' disease within the MHC in the Japanese population. J Hum Genet, 56(11):772-778, 2011

鍋島グループ

原 著>

2018

1. Kinoshita Y, Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Hiroshima K, Oda Y, Nabeshima K : A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma. Cancer, 126(1):54-63, 2018

2. Naito R, Koga K, Masaki M, Fujii N, Ito K, Koga M, Imafuku S: Multiple verrucous lesions of the feet in Waldenstrom macroglobulinemia. Clin Exp Dermatol, 2018 in press

2017年

1. Bekki H, Kohashi K, Yamada Y, Iura K, Ishii T, Maekawa A, Otsuka H, Yamamoto H, Hakozaki M, Nabeshima K, Iwamoto Y, Oda Y: Pathobiology. Phosphorylation of STAT3 in Undifferentiated Pleomorphic Sarcoma Is Correlated with a Favorable Prognosis. Pathobiology, 84: 161-169, 2017

2. Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K: Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry. Lung Cancer, 104: 98-105, 2017

3. Wu D, Hiroshima K, Yusa T, Ozaki D, Koh E, Sekine Y, Matsumoto S, Nabeshima K, Sato A, Tsujimura T, Yamakawa H, Tada Y, Shimada H, Tagawa M: Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma. Ann Diagn Pathol, 26:31-37, 2017

4. Abe S, Yamashita SI, Miyahara SO, Wakahara J, Yamamoto L, Mori R, Imamura N, Yoshida Y, Waseda R, Hiratsuka M, Shiraishi T, Nabeshima K, Iwasaki A: Prognostic Significance of BMI-1 But Not MEL-18 Expression in Pulmonary Squamous Cell Carcinoma. Anticancer Res, 37(4):1923-1929, 2017

5. Kobayashi H, Hamasaki M, Morishita T, Inoue T, Nabeshima K: Analysis of Evolving Clinicopathological Features of Metastatic Brain Tumors Over 30 Years of Surgical Management. Anticancer Res, 37(7):3969-3974, 2017

6. Marchevsky AM, LeStang N, Hiroshima K, Pelosi G, Attanoos R, Churg A, Chirieac L, Dacic S, Husain A, Khoor A, Klebe S, Lantuejoul S, Roggli V, Vignaud JM, Weynard B, Sauter J, Henderson D, Nabeshima K, Galateau-Salle F: The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Hum Pathol, 67:160-168, 2017

7. Aoki M, Koga K, Hamasaki M, Egawa N, Nabeshima K : Emmprin, released as a microvesicle in epithelioid sarcoma, interacts with fibroblasts. Int J Onco, 50(6):2229-2235, 2017

8. Yoshimura M, Kinoshita Y, Hamasaki M, Matsumoto S, Hida T, Oda Y, Nabeshima K : Diagnostic application of BAP1 immunohistochemistry to differentiate pleural mesothelioma from metastatic pleural tumours. Histopathology, 71(6):1011-1014, 2017

9. Hamasaki M, Chang KHF, Nabeshima K, Tauchi-Nishi PS : Intraoperative Squash and Touch Preparation Cytology of Brain Lesions Stained with H+E and Diff-Quik™: A 20-Year Retrospective Analysis and Comparative Literature Review. Acta Cytol, Oct 5. doi: 10.1159/000480063. [Epub ahead of print], 2017

10. Hashino Y, Nishio J, Maeyama A, Aoki M, Nabeshima K, Yamamoto T : Intra-articular angiofibroma of soft tissue of the knee: A case report . Mol Clin Oncol, 7(2):229-232, 2017

11. Miyazaki M, Aoki M, Oba S, Sakata T, Nakagawa T, Nabeshima K : A rare case of dedifferentiated liposarcoma of the sinonasal cavity: A case report. Mol Clin Oncol, Oct;7(4):539-542, 2017

12. Maeda T, Suzuki A, Koga K, Miyamoto C, Maehata Y, Ozawa S, Hata RI, Nagashima Y, Nabeshima K, Miyazaki K, Kato Y: TRPM5 mediates acidic extracellular pH signaling and TRPM5 inhibition reduces spontaneous metastasis in mouse B16-BL6 melanoma cells. Oncotarget, 2017 in press

13. Koga K, Nakaura J, Koga M, Imafuku S, Nabeshima K: Pigmented epidermotropic metastasis from breast carcinoma. J Dermatol, 44 (12): 1414-1416, 2017

2016年

1. Yoshida Y, Nagata N, Tsuruta N, Kitasato Y, Wakamatsu K, Yoshimi M, Ishii H, Hirota T, Hamada N, Fujita M, Nabeshima K, Kiyomi F, Watanabe K : Heterogeneous clinical features in patients with pulmonary fibrosis showing histology of pleuroparenchymal fibroelastosis. Respir Investig, 54: 162-169, 2016

2. Ishii T, Kohashi K, Iura K, Maekawa A, Bekki H, Yamada Y, Yamamoto H, Nabeshima K, Kawashima H, Iwamoto Y, Oda Y : Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas. Tumor Biol, 37: 4767-4776, 2016

3. Tatsukawa R, Koga K, Aoki M, Koshikawa N, Imafuku S, Nakayama J, Nabeshima K : Immunohistochemical demonstration of EphA2 processing by MT1-MMP in invasive cutaneous squamous cell carcinoma. Virchows Arch, 469(1):25-34, 2016

4. Hamasaki M, Matsumoto S, Abe S, Hamatake D, Kamei T, Hiroshima K, Kawahara K, Sato A, Tsujimura T, Nakatani Y, Yoshida Y, Iwasaki A, Nabeshima K : Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma. Lung Cancer, 99: 155-161, 2016

5. Hiroshima K, Wu D, Hasegawa M, Koh E, Sekine Y, Ozaki D, Yusa T, Walts AE, Marchevsky AM, Nabeshima K, Tada Y, Shimada H, Tagawa M : Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16. Diagn Cytopathol, 44(7):591-8, 2016.

6. Hida T, Hamasaki M, Matsumoto S, Sato A, Tsujimura T, Kawahara K, Iwasaki A, Okamoto T, Oda Y, Honda H, Nabeshima K : BAP1 immunohistochemistry and p16 FISH results in combination provide higher confidence in malignant pleural mesothelioma diagnosis: ROC analysis of the two tests. Pathol Int, 66(10):563-570, 2016.

7. Nabeshima K, Matsumoto S, Hamasaki M, Hida T, Kamei T, Hiroshima K, Tsujimura T, Kawahara K: Use of p16 FISH for differential diagnosis of mesothelioma in smear preparations. Diagn Cytopathol, 44(9):774-80, 2016

8. Bekki H, Kohashi K, Yamada Y, Iura K, Ishii T, Maekawa A, Otsuka H, Yamamoto H, Hakozaki M, Nabeshima K, Iwamoto Y, Oda Y : Pathobiology. Phosphorylation of STAT3 in Undifferentiated Pleomorphic Sarcoma Is Correlated with a Favorable Prognosis. Pathobiology, 2016 Sep 22. [Epub ahead of print]

2015年

1. Miyahara S, Hamasaki M, Hamatake D, Yamashita SI, Shiraishi T, Iwasaki A, Nabeshima K : Clinicopathological analysis of pleomorphic carcinoma of the lung: Diffuse ZEB1 expression predicts poor survival. Lung Cancer, 87: 39-44, 2015

2. Iwasaki H, Ishiguro M, Nishio J, Aoki M, Yokoyama R, Yokoyama K, Taguchi K, Nabeshima K : Extensive lipoma-like changes of myxoid liposarcoma: morphologic, immunohistochemical, and molecular cytogenetic analyses. Virchows Archiv, 466: 453-464, 2015

3. Emoto M, Yano K, Choijamts B, Sakai S, Hirasawa S, Wakamori S, Aizawa M, Nabeshima K, Tachibana K, Kanomata N : Azaspirene Analogs Inhibit the Growth of Human Uterine Carcinosarcoma In Vitro and In Vivo. Anticancer Res, 35: 2739-2746, 2015

4. Hirota T, Yoshida Y, Kitasato Y, Yoshimi M, Koga T, Tsuruta N, Minami M, Harada T, Ishii H, Fujita M, Nabeshima K, Nagata N, Watanabe K : Histological evolution of pleuroparenchymal fibroelastosis. Histopathology, 66(4):545-54, 2015

5. Ito T, Hamasaki M, Matsumoto S, Hiroshima K, Tsujimura T, Kawai T, Shimao Y, Marutsuka K, Moriguchi S, Maruyama R, Miyamoto S, Nabeshima K : p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer. Am J Clin Pathol, 143(6):830-838, 2015

6. Mizoguchi M, Hayashi H, Nabeshima K, Iwaski H, Takeshita M : Crystalloids of prostatic adenocarcinoma on prostatectomy. Med Bull Fukuoka Univ, 42(2): 223-227, 2015

7. Koshikawa N, Hoshino D, Taniguchi H, Minegishi T, Tomari T, Nam SO, Aoki M, Sueta T, Nakagawa T, Miyamoto S, Nabeshima K : Weaver AM, Seiki M. Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein. Cancer Res, 75: 3327-39, 2015

8. Hida T, Matsumoto S, Hamasaki M, Kawahara K, Tsujimura T, Hiroshima K, Kamei T, Taguchi K, Iwasaki A, Oda Y, Honda H, Nabeshima K : Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue. Cancer Sci, 106: 1635-1641, 2015

9. Okado Y, Aoki M, Hamasaki M, Koga K, Sueta T, Shiratsuchi H, Oda Y, Nakagawa T, Nabeshima K : Tumor budding and laminin5‑γ2 in squamous cell carcinoma of the external auditory canal are associated with shorter survival. SpringerPlus, 4: 814, 2015 (11 pages)

10. Bekki H, Kohashi K, Maekawa A, Yamada Y, Yamamoto H, Harimaya K, Hakozaki M, Nabeshima K, Iwamoto Y, Oda Y : Elevated expression of HSP90 and the antitumor effect of an HSP90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic sarcoma. BMC Cancer, 15:804, 2015 doi: 10.1186/s12885-015-1830-8.

11. Nguyen TT, Hachisuga T, Urabe R, Kurita T, Seiji Kagami S, Kawagoe T, Shimajiri S, Nabeshima K : Significance of p53 expression in background endometrium in endometrial carcinoma. Virchows Arch, 466:695–702, 2015

12. Hida T, Hamasaki M, Matsumoto S, Abe S, Takakura K, Hiroshima K, Nabeshima K : Diffuse intrapulmonary malignant mesothelioma presenting with miliary pulmonary nodules: A case report. Pathol Int, 65(6):318-23, 2015

2014年

1. Ono K, Nimura S, Nishinakagawa T, Nideshima Y, Enjyoji M, Nabeshima K, Nakashima M : Sodium 4-phenylbutyrate suppresses the development of dextran sulfate sodium-induced colitis in mice. Experimental and Therapeutic Medicine, 7: 573-578, 2014

2. Nomiyama T, Kawanami T, Irie S, Hamaguchi Y, Terawaki Y, Murase K, Tsutsumi Y, Nagaishi R, Tanabe M, Morinaga H, Tanaka T, Mizoguchi M, Nabeshima K, Tanaka M, Yanase T : Exendin-4, a glucagon-like peptide-1 receptor agonist, attenuates prostate cancer growth. Diabetes, 63(11):3891-905, 2014

3. Shibata R, Nimura S, Hashimoto T, Miyake T, Takeno S, Hoshino S, Nabeshima K, Yamashita Y : Expression of human epidermal growth factor receptor 2 in primary and paired parenchymal recurrent and/or metastatic sites of gastric cancer. Mol Clin Oncol, 2(5): 751-755, 2014

4. Enomoto Y, Yamashita SI, Yoshinaga Y, Fukami Y, Miyahara S, Nabeshima K, Iwasaki A : Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer. Tumor Biol, 35(11):11021-5, 2014

5. Matsumoto S, Nabeshima K, Hamasaki M, Shibuta T, Umemura T : Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component. Med Oncol, 31(12):303, 2014

6. Satoh K, Nimura S, Aoki M, Hamasaki M, Koga K, Iwasaki H, Yamashita Y, Kataoka H, Nabeshima K : Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: Possible involvement of c-Met. Cancer Sci, 105(11):1487-1495, 2014

2013年

1. Yoshinaga Y, Enomoto Y, Fujimitsu R, Shimakura M, Nabeshima K, Iwasaki A: Image and pathological changes after radiofrequency ablation of invasive breast cancer: A pilot study of nonsurgical therapy of early breast cancer. World J Surg, 37: 356-363, 2013

2. Harada T, Watanabe K, Nabeshima K, Hamasaki M, Iwasaki H: The prognostic significance of fibroblastic foci in usual interstitial pneumonia and nonspecific interstitial pneumonia. Respirology, 18: 278-283, 2013

3. Mogi A, Koga K, Aoki M, Hamasaki M, Uesugi N, Iwasaki A, Shirakusa T, Tamura K, Nabeshima K: Expression and role of GLUT-1, MCT-1, and MCT-4 in malignant pleural mesothelioma. Virchows Archiv, 462: 83-93, 2013

4. Ohishi J, Aoki M, Nabeshima K, Suzumiya J, Takeuchi T, Ogose A, Hakozaki M, Yamashita Y and Iwasaki H: Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheathtumors in vitro and in vivo through suppression of PDGFR-β. BMC Cancer, 13: 224, 2013

5. Aoki M, Nabeshima K, Hayashi H, Hamasaki M, Iwasaki H: Identification of APN/CD13 as the target antigen of FU3, a human monoclonal antibody that recognizes malignant fibrous histiocytoma. Int J Oncol, 43: 57-62, 2013

6. Higurashi N, Uchida T, Lossin C, Misumi Y, Okada Y, Akamatsu W, Imaizumi Y, Zhang B, Nabeshima K, Mori MX, Katsurabayashi S, Shirasaka Y, Okano H, Hirose S: A human Dravet syndrome model from patient induced pluripotent stem cells. Mol Brain, 6: 19, 2013 (published online) 

7. Miyake T, Nimura S, Hamada Y, Nabeshima K, Shinohara T, Tanaka S, Yamashita Y, Takeshita M, Iwasaki H: MK-1 expression in gastric carcinoma with liver metastasis. Jpn J Clin Oncol, 43: 377-382, 2013

8. Matsumoto S, Nabeshima K, Kamei T, Hiroshima K, Kawahara K, Hata S, Marukawa K, Matsuno Y, Taguchi K, Tsujimura T: Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology. Cancer Cytopathol, 121: 415-22, 2013

9. Hirota T, Fujita M, Matsumoto T, Higuchi T, Shiraishi T, Minami M, Okumura M, Nabeshima K, Watanabe K: Pleuroparenchymal fibroelastosis as a manifestation of chronic lung rejection? Eur Respir J, 41: 243-245, 2013

10. Wu D, Hiroshima K, Matsumoto S, Nabeshima K, Yusa T, Ozaki D, Fujino M, Yamakawa H, Nakatani Y, Tada Y, Shimada H, Tagawa M: Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis. Am J Clin Pathol, 139: 39-46, 2013

11. Nimura S, Iwashita A, Sato K, Shiwaku H, Nabeshima K, Takeshita M: Villous tumors of the large intestine: Pathological features and mucin phenotypic expression. Med Bull Fukuoka Univ, 40: 15-24, 2013

12. Nimura S, Iwashita A, Tsuda S, Shiwaku H, Sato K, Furukawa K, Nakashima A, Nabeshima K, Takeshita M: Pathological features of colorectal laterally spreading tumors. –Differences and similarities between gradular and non-granular type- Med Bull Fukuoka Univ, 40: 25-34, 2013

13. Koga K, Hamasaki M, Kato F, Aoki M, Hayashi H, Iwasaki A, Kataoka H, Nabeshima K: Association of c-Met phosphorylation with micropapillary pattern and small cluster invasion in pT1-size lung adenocarcinoma. Lung Cancer, 82: 413-419, 2013

14. Hayashi H, Wakuta N, Ueba T, Inoue T, Nabeshima K: Fluorescence in situ hybridization (FISH) cut-off value: Loss of heterozygosity (LOH) on 1p and 19q in oligodendroglial and oligoastrocytic tumors and glioblastomas with an oligodendroglial component. Med Bull Fukuoka Univ, 40: 111-117, 2013

2012年

1. Nishio J, Aoki M, Nabeshima K, Iwasaki H, Naito M : Cytogenetic and molecular cytogenetic findings in giant dedifferentiated liposarcoma of the thigh. Oncology Reports, 27:764-768, 2012

2. Nambu M, Matsumoto S, Takeshita M, Nabeshima K, Iwashita A : A multivariate statistical study to obtain effective criteria to detect well-differentiated adenocarcinoma in endometrial cytology. Diagn Cytopathol, 40(8):701-707, 2012

3. Mizoguchi M, Ishiguro M, Hamasaki M, Nabeshima K, Takeshita M, Iwasaki H, Iwata Y : Histologic and immunohistochemical features of pseudohyperplastic prostatic adenocarcinoma on prostatectomy. Med Bull Fukuoka Univ, 39(2):53-57, 2012.

4. Kato F, Hamasaki M, Miyake Y, Iwasaki A, Iwasaki H, Nabeshima K : Clinicopathological characteristics of subcentimeter adenocarcinomas of the lung. Lung Cancer, 77(3):495-500, 2012

5. Hamasaki M, Kato F, Koga K, Hayashi H, Aoki M, Miyake Y, Iwasaki A, Nabeshima K : Invasion of the inner and outer layers of the visceral pleura in pT1 size lung adenocarcinoma measuring ≤3 cm: correlation with malignant aggressiveness and prognosis. Virchows Arch, 461(5):513-519, 2012

6. Fukuoka M, Hamasaki M, Koga K, Hayashi H, Aoki M, Kawarabayashi T, Miyamoto S, Nabeshima K : Expression patterns of emmprin and monocarboxylate transporter-1 in ovarian epithelial tumors. Virchows Archiv, 461:457-466, 2012

2011年

1. Koshikawa N, Mizushima H, Minegishi T, Eguchi F, Yotsumoto F, Nabeshima K, Miyamoto S, Mekada E, Seiki M : Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells. Cancer Sci, 102:111-116, 2011

2. Wang W, Takashima S, Segawa Y, Itoh M, Shi X, Hwang SK, Nabeshima K, Takeshita M, Hirose S : The developmental changes of Na(v)1.1 and Na(v)1.2 expression in the human hippocampus and temporal lobe. Brain Res, 1389:61-70, 2011

3. Koga K, Aoki M, Sameshima T, Hamasaki M, Egawa N, Seiki M, Toole BP, Suzumiya J, Nabeshima K : Synthetic emmprin peptides inhibit tumor cell-fibroblast interaction-stimulated upregulation of MMP-2 and tumor cell invasion. Int J Oncol, 39(3):657-664, 2011

4. Kawakami T, Sameshima T, Hojo H, Koga K, Nakahara Y, Toole BP, Suzumiya J, Okada Y, Iwasaki A, Nabeshima K : Synthetic emmprin peptides with chitobiose substitution stimulate MMP-2 production by fibroblasts. BMC Cancer, 11:300, 2011

5. Hamasaki H, Koga K, Hamasaki M, Kiryu H, Nakayama J, Iwasaki H, Nabeshima K : Immunohistochemical analysis of laminin 5-γ2 chain expression for differentiation of basal cell carcinoma from trichoblastoma. Histopathology, 59(1):159-161, 2011

6. Hamasaki H, Koga K, Aoki M, Hamasaki M, Koshikawa N, Seiki M, Iwasaki H, Nakayama J, Nabeshima K : Expression of laminin 5-γ2 chain in cutaneous squamous cell carcinoma and its role in tumour invasion. Br J Cancer, 105(6):824-832, 2011

宮本グループ

原 著>

2018年

1. Araki R, Urushiyama D, Kiyoshima C, Yotsumoto F, Murata M, Tanaka S, Nomiyama M, Fujita M, Miyagawa T, Miyamoto S:Clinical Significance of Preterm Fetal Cardiotocography in Severe Fetal Acidemia. Med Bull Fukuoka Univ, In press

2. Itoh H, Mogami H, Nemer LB, Word L, Rogers D, Miller R, Word RA:Endometrial stromal cell attachment and matrix homeostasis in abdominal wall endometriomas. Human Reproduction, 33:280-291, 2018

2017年

1. Miyamoto S, Yotsumoto F, Ueda T, Fukami T, Sanui A, Miyata K, Nam SO, Fukagawa S, Katsuta T, Maehara M, Kondo H, Miyahara D, Shirota K, Yoshizato T, Kuroki M, Nishikawa H, Saku K, Tsuboi Y, Ishitsuka K, Takamatsu Y, Tamura K, Matsunaga A, Hachisuga T, Nishino S, Odawara T, Maeda K, Manabe S, Ishikawa T, Okuno Y, Ohishi M, Hikita T, Mizushima H, Iwamoto R, Mekada E: BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study. BMC Cancer, 17(1): 89, 2017

2. Fukagawa S, Miyata K, Yotsumoto F, Kiyoshima C, Nam SO, Anan H, Katsuda T, Miyahara D, Murata M, Yagi H, Shirota K, Yasunaga S, Kato K, Miyamoto S:MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer. Cancer Sci, 108(5):886-896, 2017  

3. Miyata K, Yotsumoto F, Fukagawa S, Kiyoshima C, Nam SO, Urushiyama D, Ito T, Katsuda T, Kurakazu M, Araki R, Sanui A, Miyahara D, Murata M, Shirota K, Yagi H, Takono T, Kato K, Yaegashi N, Akazawa K, Kuroki M, Yasunaga S and Miyamoto S:Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer. Anticancer Res, 37: 3955-3960, 2017

4. Fukagawa S, Yotsumoto F, Odawara T, Manabe S, Ishikawa T, Yasunaga S, Miyamoto S:Antitumour Effects of Intravenous Administration of BK-UM, a Novel Inhibitor of HB-EGF, in Ovarian Cancer Therapy. Anticancer Res, 37: 3891-3896, 2017

5. Yotsumoto F, Fukagawa S, Miyata K, Nam SO, Katsuda T, Miyahara D, Odawara T, Manabe S, Isikawa T, Yasunaga S, Miyamoto S:HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of EGFRT790M. Anticancer Res, 37: 3825-3831, 2017

6. Urushiyama D, Suda W, Ohnishi E, Araki R, Kiyoshima C, Kurakazu M, Sanui A, Yotsumoto F, Murata M, Nabeshima K, Yasunaga S, Saito S, Nomiyama M, Hattori M, Miyamoto S & Hata K:Microbiome profile of the amniotic fluid as a predictive biomarker of perinatal outcome. SCIENTIFIC Reports, 7(1):12171, 1217

2016年

1. Shirota K, Yotsumoto F, Itoh H, Obama H, Hidaka N, Nakajima K, Miyamoto S:Separation efficiency of a microfluidic sperm sorter to minimize sperm DNA damage. Fertility and Sterility, 105:315-321, 2016

2. Yoshizato T, Kimura I, Araki R, Sanui A, Yotsumoto F, Miyamoto S:Age-related changes in the thickness of the anterior lower uterine segment in normal singleton pregnancy from 20-35 weeks' gestation. J Med Ultrasonics, 43: 401-405, 2016

3. Miyahara D, Katsuda T, Maehara M, Takahashi Y, Fukagawa S, Miyata K, Kiyoshima C, Yotsumoto F, Anan H, Miyamoto S: Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer. Anticancer Res, 36:3725-3730, 2016

2015年

1. Nam SO, Yotsumoto F, Miyata K, Fukagawa S, Yamada H, Kuroki M, Miyamoto S:Warburg effect regulated by amphiregulin in the development of colorectal cancer. Cancer Medicine, 4:575-587, 2015

2. Miyata K, Miyata T, Nakabayashi K, Okamura K, Naito M, Kawai T, Takada S, Miyamoto S, Hata K, Asahara H:DNA methylation analysis of human myoblasts furing in vitro myogenic differentiation; de novo methylation of promoters of muscle-related genes and its involvement in transcriptional down-regulation. Hum Mol Gene, 24:410-423, 2015

3. Ito T, Hamasaki M, Matsumoto S, Hiroshima K, Tsujimura T, Kawai T, Shimao Y, Marutsuka K, Moriguchi S, Maruyama R, Miyamoto S, Nabeshima K:p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma from Mesothelial Hyperplasia and Epithelial Ovarian Cance. Am J Clin Pathol, 143:1-9, 2015

4. Maehara M, Ueda T, Miyahara D, Takahashi Y, Miyata K, Nam SO, Katsuda T, Kondo H, Miyamoto S:Clinical efficacy of aprepitant in patients with gynecological cancer after chemotherapy using paclitaxel and carboplatin. Anticancer Res, 35:4527-4534, 2015

5. Miyahara D, Ueda T, Katsuda T, Maehara M, Fukagawa S, Miyata K, Nam SO, Kondo H, Miyamoto S:The safety of pegylated liposomal docxorubicin plus irinotecan in recurrent ovarian cancer pateints: A phase I trial. Anticancer Res, 35:4521-4526, 2015

6. Nam SO, Yotsumoto F, Miyata K, Souzaki R, Taguchi T, Kuroki M, Miyamoto S:Validity of HB-EGF as Target for Human Neuroblastoma Therapy. Anticancer Res, 35:4433-4440, 2015

7. Goto M, Yoshizato T, Tatsumura M, Takashima T, Ogawa M, Nakahara H, Satoh S, Sanui A, Eguchi F, Miyamoto S:Safety and efficacy of thromboprophylaxis using enoxaparin sodium after cesarean section: A multi-center study in Japan. Taiwanese Journal of Obstetrics & Gynecology, 54:248-252, 2015

8. Nojiri T, Yoshizato T, Sanui A, Araki R, Obama H, Shirota K, Miyamoto S:Proposal of a new parameter for diagnosing a low-lying placenta in the third trimester: The distance between the external os and Placental edge. Taiwanese Journal of Obstetrics & Gynecology, 54: 390-393, 2015

2014年

1. Gondo S, Urushiyama D, Yoshizato T, Kora S, Maehara M, Kondo H, Miyamoto S : The successful detection of postpartum unruptured vaginal pseudoaneurysm using ultrasonography: a case report. Springerplus, 3: 482, 2014

2. Urushiyama D, Yoshizato T, Kora S, Higashihara H, Sato A, Kubota T, Tatsumura M, Yoshimitsu K, Miyamoto S : Predictive factors related to the efficacy of pelvic arterial embolization for postpartum hemorrhage: a retrospective analysis of 21 cases. Taiwan J Obstet Gynecol, 53: 366-71, 2014

3. Miyata K, Yotsumoto F, Nam SO, Odawara T, Manabe S, Ishikawa T, Itamochi H, Kigawa J, Takada S, Asahara H, Kuroki M, Miyamoto S : Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma. Cancer Med, 3: 1159-69, 2014

4. Nam SO, Yotsumoto F, Miyata K, Suzaki Y, Yagi H, Odawara T, Manabe S, Ishikawa T, Kuroki M, Mekada E, Miyamoto S : Pre-clinical study of BK-UM, a novel inhibitor of HB-EGF, for ovarian cancer therapy. Anticancer Res, 34: 4615-20, 2014

5. Kurakazu M, Yoshizato T, Miyake Y, Goto M, Eguchi F, Miyamoto S : Rapid progression of Nulliparous labor increases the risk of preterm delivery in a subsequent pregnancy. Med Bull Fukuoka Univ, 41: 65-70, 2014

6. Goto M, Yosizato T, Miyamoto S : Safety and efficacy of thromboprophylaxis using enoxaparin sodium after cesarean section: A multi-center study in Japan. Taiwanese Journal of Obstetrics & Gynecology. 2014 (in press)

7. Miyata K, Miyata T, Nakabayashi K, Okamura K, Naito M, Kawai T, Takada S, Kato K, Miyamoto S, Hata K, Asahara H : DNA methylation analysis of human myoblasts during in vitro myogenic differentiation: de novo methylation of promoters of muscle-related genes and its involvement in transcriptional down-regulation. Hum Mol Genet, 24: 410-423, 2014

2013年

1. Yotsumoto F, Tokunaga E, Oki E, Maehara Y, Yamada H, Nakajima K, Nam SO, Miyata K, Koyanagi M, Doi K, Shirasawa S, Kuroki M, Miyamoto S: Molecular Hierarchy of Heparin-Binding EGF-like Growth Factor-Regulated Angiogenesis in Triple-Negative Breast Cancer. Mol Cancer Res, 11:506-517, 2013

2. Kato T, Miyata K, Sonobe M, Yamashita S, Tamano M, Miura K, Kanai Y, Miyamoto S, Sakuma T, Yamamoto T, Inui M, Kikusui T, Asahara H, Takada S: Production of Sry knockout mouse using TALEN via oocyte injection. Scientific Reports, 3:3136, 2013

3. Itho H, Kawano Y, Furukawa Y, Matsumoto H, Yuge A, Narahara H : The role of serum adiponectin levels in woman with polycystic ovarian syndrome. Clin Exp Obstet Gynecol, 40: 531-535, 2013

4. Yoshikane Y, Yoshizato T, Otake Y, Yamaura K, Hirose S, Miyamoto S : Prenatal Diagnosis of High Grade Atrioventricular Block with Polymorphic Ventricular Premature Contractions due to Congenital Long QT Syndrome Using Doppler Flow Recording. Med Bull Fukuoka Univ, 4: 67–71, 2013

2012年

1. Ueda T, Maehara M, Takahashi Y, Nakayama N, Kondo H, Shirota K, Yoshizato T, Miyamoto S: Clinical significance of cell-free and concentrated ascites re-infusion therapy for advanced and recurrent gynecological cancer. Anticancer Res, 32(6):2353-7, 2012

2. Nojiri T, Yoshizato T, Fukami T, Obama H, Yagi H, Yotsumoto F, Miyamoto S: Clinical significance of amphiregulin and epidermal growth factor in colostrum. Arch Gynecol Obstet, 286(3):643-7, 2012

3. Ota T, Doi K, Fujimoto T, Tanaka Y, Ogawa M, Matsuzaki H, Kuroki M, Miyamoto S, Shirasawa S, Tsunoda T: KRAS up-regulates the expression of miR-181a, miR-200c and miR-210 in a three-dimensional-specific manner in DLD-1 colorectal cancer cells. Anticancer Res, 32(6): 2271-2276, 2012

4. Ohchi T, Akagi Y, Kinugasa T, Kakuma T, Kawahara A, Sasatomi T, Gotanda Y, Yamaguchi K, Tanaka N, Ishibashi Y, Miyamoto S, Kage M, Shirouzu K: Amphiregulin is a prognostic factor in colorectal cancer. Anticancer Res, 32(6): 2315-2321, 2012

5. Yoshikane Y, Yoshizato T, Otake Y, Fusazaki N, Obama H, Miyamoto S, Hirose S: Four-year experience with prenatal diagnosis of congenital heart defects at a single referral center in Japan with focus on inaccurately diagnosed cases. J Med Ultrasonics, 39 : 235-240, 2012

6. Kasai N, Kovayashi K, Shioya S, Yoshikawa Y, Yotsumoto F, Miyamoto S, Mekada E, Enokizono J: Soluble heparin-binding EGF-like growth factor (HB-EGF) detected by newly developed immuno-PCR method is a clear-cut serological biomarker for ovarian cancer. Am J Transl Res, 4: 415-421, 2012

7. Tsunoda T, Ota T, Fujimoto T, Doi K, Tanaka Y, Yoshida Y, Ogawa M, Matsuzaki H, Hamabashiri M, Tyson DR, Kuroki M, Miyamoto S, Shirasawa S: Inhibition of phosphodiesterase-4 (PDE4) activity triggers luminal apoptosis and AKT dephosphorylation in a 3-D colonic-crypt model. Molecular Cancer, 11 (1):46, 2012

8. Kurakazu M, Ueda T, Matsuo K, Ishikura H, Kumagai N, Yoshizato T, Miyamoto S: Percutaneous cardiopulmonary support for pulmonary thromboembolism caused by large uterine leiomyoma. Taiwanese Journal of Obstetrics & Gynecology, 51:639-642, 2012

9. Fukuoka M, Hamasaki M, Koga K, Hayashi H, Aoki M, Kawarabayashi T, Miyamoto S, Nabeshima K: Expression patterns of emmprin and monocarboxylate transporter-1 in ovarian epithelial tumors. Virchows Arch, 461(4):457-66, 2012.

10. Yotsumoto F, Kuroki M, Miyamoto S: Biological characteristics of ovarian cancer: Nihon Rinsho, 70 Suppl 4:488-92, 2012

11. Kuroki M, Miyamoto S, Morisaki T, Yotsumoto F, Shirasu N, Taniguchi Y, Soma G: Biological response modifiers used in cancer biotherapy. Anticancer Res, 32 (6):2229-33, 2012

12. Ishitsuka K, Kunami N, Katsuya H, Nogami R, Ishikawa C, Yotsumoto F, Tanji H, Mori N, Takeshita M, Miyamoto S, Tamura K: Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Cancer Lett, 28; 317(2):218-25, 2012

2011年

1. Tsujioka H, Yotsumoto F, Hikita S, Shirota K, Ueda T, Kuroki M, Miyamoto S: Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy. Current Opinion in Obstet Gynecol, 23:24-30, 2011

2. Masumoto K, Kai H, Oka Y, Otake R, Yoshizato T, Miyamoto S, Hirose S, Hamasaki M, Nabeshima K, Iwasaki A: A case of cystic biliary atresia with an antenatally detected cyst: the possibility of changing from a correctable type with a cystic lesion ( I cyst ) to an uncorrectable one (IIId). Pediatr Surg Int, 27 : 99-102, 2011

3. Choijamuts B, Naganuma Y, Nakajima K, Kawarabayashi T, Miyamoto S, Tachibana K, Emoto M: Metoronomic irinotecan chemotherapy combined with ultrasound irradiation for a human uterine sarcoma xenograft. Cancer Sci, 102:452-459, 2011

4. Koshikawa N, Mizushima H, Minegishi T, Eguchi F, Yotsumoto F, Nabeshima K, Miyamoto S, Mekada E, Seiki M: Proteolytic activation of heparin-binding EGF-like growth factor by membrane-type matrix metalloproteinase-1 in ovarian carcinoma cells. Cancer Sci, 102:111-116, 2011

5. Hikita S, Yotsumoto F, Fkami T, Horiuchi S, Sanui A, Miyata K, Nam S, Tsujioka H, Ueda T, Shirota K, Yoshizato T, Maeda K, Ishikawa T, Okuno Y, Kuroki M, Mekada E, Miyamoto S: Assessment of HB-EGF levels in peritoneal fluid and serum of ovarian cancer patients using ELISA. Anticancer Res, 31:2553-2560, 2011

6. Naganuma Y, Choijamts B, Shirota K, Nakajima K, Ogata S, Miyamoto S, Kawarabayashi T, Emoto M: Metronomic doxifluridine chemotherapy combined with the anti-angiogenic agent TNP-470 inhibits the growth of human uterine carcinosarcoma xenografts. Cancer Sci, 102: 1542-1552, 2011

7. Miyamoto S, Iwamoto R, Furuya A, Takahashi K, Sasaki Y, Ando H, Yotsumoto F, Yoneda T, Hamaoka M, Yagi H, Murakami T, Hori S, Shitara K, Mekada E: A Novel Anti-Human HB-EGF Monoclonal Antibody with Multiple Anti-Tumor Mechanisms Against Ovarian Cancer Cells. Clin Cancer Res, 17:6733-6741, 2011

8. Emoto M, Sadamori R, Hachisuga T, Kawarabayashi T, Miyamoto S: Clinical usefulness of contrast-enhanced color doppler ultrasonography in invasive and noninvasive gestational trophoblastic diseases A preliminary study. J Reprod Med, 56:224-234, 2011

9. Kunami N, Yotsumoto F, Ishitsuka K, Fukami T, Odawara T, Manabe S, Ishikawa T, Tamura K, Kuroki M, Miyamoto S: Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia. Aanticancer Res, 31:2483-2488, 2011

10. Ishitsuka K, Tsukasaki K, Tamura K: Interferon alfa and antiretroviral agents: a treatment option for adult T-cell leukemia/lymphoma. Drugs Today, 47(8): 615-23, 2011

11. Miyazaki M, Takata T, Yoshimura H, Matsunaga A, Ohta D, Ishikura H, Futo M, Hara S, Kamimura H, Tamura K, Ngo D, Tsuji BT.: Vancomycin bactericidal activity as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother, 55(4): 1819-20, 2011

12. Nakano D, Ishitsuka K, Hatsuse T, Tsuchihashi R, Okawa M, Okabe H, Tamura K, Kinjo J: Screening of promising chemotherapeutic candidates against human adult T-cell leukemia/lymphoma from plants: active principles from Physalis pruinosa and structure-activity relationships with withanolides. J Nat Med, 65(3-4): 559-67, 2011

13. Ushijima K, Kamura T, Tamura K, Kuzuya K, Sugiyama T, Noda K, Ochiai K: Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study. Int J Clin Oncol, 2011 Nov 30. [Epub ahead of print]

14. Ohata Y, Tomita Y, Nakayama M, Tamura K, Tanigawara Y: Optimal treatment schedule of meropenem for adult patients with febrile neutropenia based on pharmacokinetic- pharmacodynamics analysis. J Infect Chemother, 17:831-841, 2011